Asset Details
Do you wish to reserve the book?
Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series
Do you wish to request the book?
Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series
2023
Overview
Background Feline infectious peritonitis (FIP) is a viral disease in cats, caused by certain strains of coronavirus and has a high case fatality rate. Objective This case series reports the outcomes of treatment of cats with FIP using molnupiravir. Animals Eighteen cats diagnosed with FIP at the You‐Me Animal Clinic, Sakura‐shi, Japan between January and August 2022, and whose owners gave informed consent to this experimental treatment. Methods For this prospective observational study, molnupiravir tablets were compounded in‐house at the You‐Me Animal Clinic. Owners administered 10‐20 mg/kg PO twice daily. Standard treatment duration was 84 days. Results Among 18 cats, 13 cats had effusive FIP and 5 had noneffusive FIP. Three cats had neurological or ocular signs of FIP before treatment. Four cats, all with effusive FIP, died or were euthanized within 7 days of starting treatment. The remaining 14 cats completed treatment and remained in remission at the time of writing (139‐206 days after starting treatment). Elevated serum alanine transaminase (ALT) activity was found in 3 cats, all at Days 7‐9, and all recovered without management. Two cats with jaundice were hospitalized, 1 during treatment (Day 37) and 1 with severe anemia at the start of treatment. Conclusions and Clinical Importance This case series suggests that molnupiravir might be an effective and safe treatment for domestic cats with FIP at a dose of 10‐20 mg/kg twice daily.
We currently cannot retrieve any items related to this title. Kindly check back at a later time.